Recursion Pharmaceuticals, sell signal in week 3
Recursion drops 12.7% and slips back below its 50-week average, closing near the lows
Our view last week
Recursion gained 8.9% and retook its 50-week average, after closing below it a week ago, but the candle faded into the lower part of its range and a new 7-day high failed to hold into the close. For Recursion stock, our technical analysis reads a Sell signal with no fresh push, strength at 2 out of 100, and high risk for new shorts. Among US stocks to watch, this is a trade setup to handle with care, with earnings due on November 2.
This week's summary
Recursion drops 12.7% and wipes out last week's bounce: price slips back below its 50-week average and closes in the bottom quarter of its range. For Recursion stock, the price action points to a distribution phase, with money flow negative for 2 weeks. The sell signal is in week 3, and the second week closed higher: among US stocks, a trade setup to handle with care.
IQS Phase
66
in tension
Signal Strength
38
decline starting to make lower lows
Sizing
MINIMUM
Ranking
#103 / 181
US stocks sell signals
Trade P&L %
+4.86%
from signal to date, no stop loss
Recursion Pharmaceuticals (RXRX) weekly chart — EMA50 · MACD · VWAP
Weekly chart · EMA50 · MACD · VWAP · Source: TradingView
Rank position
ranks 103rd among the 181 sell signals for US stocks in our ranking, with a signal strength of 38 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein strong phase
Performanceweekly -0.04% · monthly +9.47%
RXRX belongs to the health care sector (reference ETF XLV). The sector is classified in strong phase according to our weekly reading.
restricted Platinum content